Hans J. Moebius - ANDERA PARTNERS :ANDERA PARTNERS

Hans J. Moebius has worked in the life science industry for decades, and currently serves as CMO at Exciva, Heidelberg, which he co-founded, developing new therapies for neuropsychiatric conditions in dementia.
From 2019-2024, he served as CMO at Athira Pharma, Seattle, USA, and was part of their 430M$ IPO at NASDAQ. He was CMO at several US (Chase, Rodin) and UK/Singapore (tauRx) biotechs, supporting successful trade sales. Hans started his industry career 1991 at Ciba/Novartis in Basel, Switzerland and has served in international leading pharma positions in neuroscience, resulting in the approval of several new CNS therapies, most notably memantine in Alzheimer’s disease which achieved blockbuster sales at 1.8 B$ per year in 2014; he is the sole inventor of Namzaric®, the first ever combination therapy in Alzheimer’s Disease, and co-inventor on several patents.
After his graduation in Heidelberg, he held a research tenure in neuropathology, then at the Max-Planck-Institute for Brain Research in Frankfurt/M, followed by university residencies in Neurology and Psychiatry and both board certifications.
Hans also holds a PhD in Experimental Pharmacology, the European Certificate in Pharmaceutical Medicine (ECPM) from the EUCOR Universities Basel/Switzerland, Freiburg/Germany and Strasbourg/France and is a fellow of the American Academy of Neurology.
He received the Innovation Award of the German Industry 2002 for the development of memantine, and the Pavlov Medal in 2018.